Inactief instrument

Andere talen Mount Magnet South Ltd Australian S.E.

Aandelen

AU000000MUM1

slotkoers Australian S.E. Andere beurzen
- ^AUD	-

07/05	Incannex Voltooit Succesvolle Pre-Ind Meeting met de Fda voor Cannquit-O voor de behandeling van Opioïde Gebruiksstoornis	CI
05/03	Incannex Healthcare Inc. kondigt wijzigingen aan in de leiding	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder	07/05
Incannex Complete Successful Pre-Ind Meeting with the Fda for Cannquit-O for Treatment of Opioid Use Disorder	07/05
Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD)	01/05
Incannex Healthcare Inc. Quarterly Update, Q1 2024	16/04
Incannex Healthcare Inc. Announces CFO Changes	05/03
Incannex Healthcare Inc. Announces Executive Changes	05/03
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder	28/02
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder	28/02
Incannex Healthcare Completes Pre-Investigational New Drug Meeting on CannQuit-N With US FDA	16/02
Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation	16/02
Incannex Healthcare Inc. Completes Successful Pre-IND Meeting with the FDA for CannQuit-N	16/02
Incannex Healthcare Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	14/02
Clarion Clinics Open for Psychedelic-Assisted Treatments	01/02
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis	24/01
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis	24/01
Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences	18/01
Incannex Completes Dosing and Therapy in Phase 2 ?Psigad? Clinical Trial Assessing Psilocybin-Assisted Psychotherapy for Generalized Anxiety Disorder	18/01
Incannex Healthcare Gets Institutional Review Board Approval For IHL-42X Drug Trial	17/01
Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	17/01
Incannex Healthcare Inc. Receives IRB Approval for the Reposa Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	17/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Mount Magnet South Ltd Australian S.E.

Aandelen

AU000000MUM1

Andere talen

Filters